Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Launched by AIO-STUDIEN-GGMBH · Apr 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding and improving treatment for patients with specific types of head and neck cancers, particularly squamous cell carcinoma affecting areas like the mouth, throat, and voice box. The goal is to gather real-world information about how these patients are treated and their outcomes, which can help in developing better treatment options in the future. The trial is currently recruiting participants who are at least 18 years old and have been diagnosed with squamous cell carcinoma in these areas. To join, patients should be receiving palliative care, which means they are receiving treatment to relieve symptoms rather than trying to cure the cancer.
Participants in this study can expect to provide information about their treatment and health outcomes over time. They will need to sign a consent form to show they understand and agree to take part in the study, which should be done within specified timeframes after starting their treatment. Importantly, there are no exclusions based on other health conditions, so many patients may be eligible to participate. This research aims to create a comprehensive understanding of how to best support patients facing these difficult diagnoses.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Able to understand and willing to sign written informed consent
- • Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
- • Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
- • Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
- • Exclusion Criteria: none
About Aio Studien Ggmbh
aio-studien-ggmbh is a leading clinical trial sponsor dedicated to advancing medical research through the design and execution of high-quality clinical studies. With a focus on innovative therapies and patient-centric approaches, aio-studien-ggmbh collaborates with healthcare professionals and organizations to facilitate the development of new treatments across various therapeutic areas. The organization is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and well-being of participants while generating reliable data to inform clinical practice and regulatory decisions. Through its expertise in trial management and operational excellence, aio-studien-ggmbh contributes significantly to the progression of healthcare and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, , Germany
Hannover, , Germany
Patients applied
Trial Officials
Victor Grünwald, Prof. Dr.
Study Director
Universitätsklinikum Essen
Michael Pogorzelski, Dr.
Principal Investigator
Universitätsklinikum Essen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported